Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$288.06 -3.6%	$296.27	$273.11 ▼ $495.55	$38.46B	0.27	1.31 million shs	2.68 million shs
AZN Astrazeneca	$169.79 -1.1%	$183.38	$137.23 ▼ $212.71	$263.32B	0.24	2.55 million shs	4.67 million shs
BBIO BridgeBio Pharma	$83.08 -3.3%	$70.00	$42.09 ▼ $93.42	$16.27B	0.95	3.15 million shs	3.38 million shs
IONS Ionis Pharmaceuticals	$56.75 -2.6%	$75.78	$40.03 ▼ $86.74	$9.38B	0.36	2.32 million shs	5.10 million shs
PFE Pfizer	$24.46 +1.2%	$25.32	$23.11 ▼ $28.75	$139.41B	0.35	42.61 million shs	42.73 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	0.00%	-4.48%	+5.62%	-10.28%	-5.14%
AZN Astrazeneca	0.00%	-11.85%	-3.88%	-15.07%	+20.81%
BBIO BridgeBio Pharma	0.00%	+11.27%	+28.58%	+10.30%	+84.83%
IONS Ionis Pharmaceuticals	0.00%	-28.79%	-20.51%	-22.28%	+39.59%
PFE Pfizer	0.00%	-0.31%	-7.54%	-11.38%	-5.59%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$288.06 -3.6%	$296.27	$273.11 ▼ $495.55	$38.46B	0.27	1.31 million shs	2.68 million shs
AZN Astrazeneca	$169.79 -1.1%	$183.38	$137.23 ▼ $212.71	$263.32B	0.24	2.55 million shs	4.67 million shs
BBIO BridgeBio Pharma	$83.08 -3.3%	$70.00	$42.09 ▼ $93.42	$16.27B	0.95	3.15 million shs	3.38 million shs
IONS Ionis Pharmaceuticals	$56.75 -2.6%	$75.78	$40.03 ▼ $86.74	$9.38B	0.36	2.32 million shs	5.10 million shs
PFE Pfizer	$24.46 +1.2%	$25.32	$23.11 ▼ $28.75	$139.41B	0.35	42.61 million shs	42.73 million shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	0.00%	-4.48%	+5.62%	-10.28%	-5.14%
AZN Astrazeneca	0.00%	-11.85%	-3.88%	-15.07%	+20.81%
BBIO BridgeBio Pharma	0.00%	+11.27%	+28.58%	+10.30%	+84.83%
IONS Ionis Pharmaceuticals	0.00%	-28.79%	-20.51%	-22.28%	+39.59%
PFE Pfizer	0.00%	-0.31%	-7.54%	-11.38%	-5.59%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALNY Alnylam Pharmaceuticals	2.85	Moderate Buy	$457.57	59.75% Upside
AZN Astrazeneca	2.80	Moderate Buy	$211.00	24.69% Upside
BBIO BridgeBio Pharma	2.83	Moderate Buy	$93.40	14.19% Upside
IONS Ionis Pharmaceuticals	2.81	Moderate Buy	$96.05	69.32% Upside
PFE Pfizer	2.19	Hold	$28.50	16.73% Upside

Current Analyst Ratings Breakdown

Latest AZN, IONS, BBIO, ALNY, and PFE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/13/2026	ALNY Alnylam Pharmaceuticals	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$505.00 ➝ $410.00
7/13/2026	AZN Astrazeneca	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold
7/13/2026	ALNY Alnylam Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$470.00 ➝ $485.00
7/13/2026	BBIO BridgeBio Pharma	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$110.00 ➝ $120.00
7/13/2026	IONS Ionis Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$100.00 ➝ $85.00
7/13/2026	PFE Pfizer	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$34.00 ➝ $30.00
7/13/2026	PFE Pfizer	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$36.00 ➝ $35.00
7/10/2026	IONS Ionis Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$115.00 ➝ $100.00
7/10/2026	IONS Ionis Pharmaceuticals	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$115.00 ➝ $90.00
7/10/2026	ALNY Alnylam Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$370.00 ➝ $400.00
7/10/2026	IONS Ionis Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$130.00 ➝ $125.00

(Data available from 7/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALNY Alnylam Pharmaceuticals	$3.71B	10.30	$2.68 per share	106.85	$5.97 per share	47.98
AZN Astrazeneca	$60.44B	4.34	$12.75 per share	13.27	$31.41 per share	5.39
BBIO BridgeBio Pharma	$502.08M	31.91	N/A	N/A	($10.77) per share	-7.59
IONS Ionis Pharmaceuticals	$944M	9.93	N/A	N/A	$3.02 per share	18.78
PFE Pfizer	$63.31B	2.20	$4.44 per share	5.50	$15.26 per share	1.60

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALNY Alnylam Pharmaceuticals	$313.75M	$3.66	78.11	28.33	N/A	11.72%	85.76%	10.32%	7/30/2026 (Estimated)
AZN Astrazeneca	$10.23B	$6.66	25.37	14.70	1.39	17.19%	30.86%	12.68%	7/27/2026 (Estimated)
BBIO BridgeBio Pharma	-$724.93M	-$3.74	N/A	629.18	N/A	-124.42%	N/A	-65.81%	8/4/2026 (Estimated)
IONS Ionis Pharmaceuticals	-$381.39M	-$2.07	N/A	N/A	N/A	-30.91%	-58.65%	-10.07%	8/5/2026 (Estimated)
PFE Pfizer	$7.77B	$1.31	18.64	8.54	N/A	11.83%	19.44%	8.41%	8/4/2026 (Estimated)

Latest AZN, IONS, BBIO, ALNY, and PFE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2026	Q2 2026	IONS Ionis Pharmaceuticals	-$0.92	N/A	N/A	N/A	$188.24 million	N/A
8/4/2026	Q2 2026	BBIO BridgeBio Pharma	-$0.64	N/A	N/A	N/A	$220.45 million	N/A
8/4/2026	Q2 2026	PFE Pfizer	$0.68	N/A	N/A	N/A	$14.45 billion	N/A
7/30/2026	Q2 2026	ALNY Alnylam Pharmaceuticals	$2.03	N/A	N/A	N/A	$1.32 billion	N/A
7/27/2026	Q2 2026	AZN Astrazeneca	$2.52	N/A	N/A	N/A	$15.47 billion	N/A
5/7/2026	Q1 2026	BBIO BridgeBio Pharma	-$0.70	-$0.84	-$0.14	-$0.84	$178.07 million	$194.52 million
5/5/2026	Q1 2026	PFE Pfizer	$0.7220	$0.75	+$0.0280	$0.47	$13.84 billion	$14.45 billion
4/30/2026	Q1 2026	ALNY Alnylam Pharmaceuticals	$0.8720	$1.99	+$1.1180	$1.51	$1.12 billion	$1.17 billion
4/29/2026	Q1 2026	AZN Astrazeneca	$2.52	$2.58	+$0.06	$0.9850	$14.93 billion	$15.29 billion
4/29/2026	Q1 2026	IONS Ionis Pharmaceuticals	-$0.85	-$0.56	+$0.29	-$0.56	$195.57 million	$246.09 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALNY Alnylam Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
AZN Astrazeneca	$4.34	2.56%	+2.30%	65.17%	N/A
BBIO BridgeBio Pharma	N/A	N/A	N/A	N/A	N/A
IONS Ionis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PFE Pfizer	$1.72	7.04%	-13.20%	131.30%	16 Years

Latest AZN, IONS, BBIO, ALNY, and PFE Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/24/2026	PFE Pfizer	quarterly	$0.43	7.15%	7/24/2026	7/24/2026	9/1/2026
4/22/2026	PFE Pfizer	quarterly	$0.43	6.71%	5/8/2026	5/8/2026	6/12/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALNY Alnylam Pharmaceuticals	0.94	3.13	3.06
AZN Astrazeneca	0.52	0.91	0.71
BBIO BridgeBio Pharma	N/A	1.52	1.48
IONS Ionis Pharmaceuticals	2.75	4.10	4.09
PFE Pfizer	0.67	1.25	0.94

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALNY Alnylam Pharmaceuticals	92.97%
AZN Astrazeneca	20.35%
BBIO BridgeBio Pharma	99.85%
IONS Ionis Pharmaceuticals	93.86%
PFE Pfizer	68.36%

Insider Ownership

Company	Insider Ownership
ALNY Alnylam Pharmaceuticals	0.86%
AZN Astrazeneca	N/A
BBIO BridgeBio Pharma	14.23%
IONS Ionis Pharmaceuticals	1.81%
PFE Pfizer	0.62%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALNY Alnylam Pharmaceuticals	2,770	133.51 million	132.37 million	Optionable
AZN Astrazeneca	96,100	1.55 billion	N/A	N/A
BBIO BridgeBio Pharma	400	195.86 million	167.99 million	Optionable
IONS Ionis Pharmaceuticals	1,402	165.26 million	162.27 million	Optionable
PFE Pfizer	75,000	5.70 billion	5.66 billion	Optionable

AZN, IONS, BBIO, ALNY, and PFE Headlines

Recent News About These Companies

Pfizer (PFE) Advances While Market Declines: Some Information for Investors

35 minutes ago | zacks.com

Pfizer (NYSE:PFE) Stock Price Up 1.2% - What's Next?

2 hours ago | marketbeat.com

Abbott Labs Vs. Pfizer: Which Discounted Healthcare Titan Screens as the Bigger Value Trap?

2 hours ago | 247wallst.com

Abbott Labs Vs. Pfizer: Which Discounted Healthcare Titan Screens as the Bigger Value Trap?

2 hours ago | 247wallst.com

2 Value Stocks Worth Your Attention and 1 Facing Headwinds

3 hours ago | finance.yahoo.com

The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions (PFE)

...

July 13 at 12:25 PM | marketbeat.com

How Does LLY Stock Reach $2,100?

July 13 at 10:30 AM | trefis.comT

What It Means To Hold Moderna Stock In A Crash

July 13 at 10:30 AM | trefis.comT

Pfizer (NYSE:PFE) Given New $30.00 Price Target at BMO Capital Markets

July 13 at 9:11 AM | marketbeat.com

Pfizer (NYSE:PFE) Price Target Cut to $35.00 by Analysts at Guggenheim

July 13 at 8:59 AM | marketbeat.com

Triglav Investments D.O.O. Has $8.89 Million Position in Pfizer Inc. $PFE

July 13 at 6:00 AM | marketbeat.com

Pfizer Inc. $PFE Shares Purchased by CORDA Investment Management LLC.

July 13 at 4:07 AM | marketbeat.com

Diversify Wealth Management LLC Has $3.35 Million Position in Pfizer Inc. $PFE

July 13 at 3:59 AM | marketbeat.com

Citizens Financial Group Inc. RI Trims Stock Holdings in Pfizer Inc. $PFE

July 13 at 3:44 AM | marketbeat.com

LGT Fund Management Co Ltd. Buys 765,044 Shares of Pfizer Inc. $PFE

July 12 at 1:44 PM | marketbeat.com

Pfizer Inc. $PFE Shares Sold by International Assets Investment Management LLC

July 12 at 1:44 PM | marketbeat.com

Pfizer Inc. $PFE Position Lifted by Fifth Third Bancorp

July 12 at 11:19 AM | marketbeat.com

Pfizer Inc. (NYSE:PFE) Receives Average Rating of "Hold" from Analysts

July 12 at 11:17 AM | americanbankingnews.com

Pfizer (PFE) Juggles Fresh Trial Wins Amid Analyst Doubt

July 11 at 11:11 AM | tipranks.com

Villere ST Denis J & Co. LLC Purchases 70,613 Shares of Pfizer Inc. $PFE

July 11 at 10:55 AM | marketbeat.com

Kornitzer Capital Management Inc. KS Grows Stock Holdings in Pfizer Inc. $PFE

July 11 at 10:40 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

AZN, IONS, BBIO, ALNY, and PFE Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

$288.06 -10.70 (-3.58%)

Closing price 04:00 PM Eastern

Extended Trading

$288.50 +0.44 (+0.15%)

As of 06:56 PM Eastern

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Astrazeneca NYSE:AZN

$169.79 -1.82 (-1.06%)

Closing price 03:59 PM Eastern

Extended Trading

$170.80 +1.01 (+0.60%)

As of 07:19 PM Eastern

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

BridgeBio Pharma NASDAQ:BBIO

$83.08 -2.81 (-3.27%)

Closing price 04:00 PM Eastern

Extended Trading

$82.42 -0.66 (-0.79%)

As of 07:15 PM Eastern

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Ionis Pharmaceuticals NASDAQ:IONS

$56.75 -1.50 (-2.58%)

Closing price 04:00 PM Eastern

Extended Trading

$56.59 -0.16 (-0.28%)

As of 07:18 PM Eastern

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

Pfizer NYSE:PFE

$24.46 +0.29 (+1.20%)

Closing price 03:59 PM Eastern

Extended Trading

$24.49 +0.03 (+0.12%)

As of 07:20 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AZN, IONS, BBIO, ALNY, and PFE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AZN, IONS, BBIO, ALNY, and PFE Earnings

Compare Dividends

Latest AZN, IONS, BBIO, ALNY, and PFE Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AZN, IONS, BBIO, ALNY, and PFE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

AZN, IONS, BBIO, ALNY, and PFE Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

Astrazeneca NYSE:AZN

BridgeBio Pharma NASDAQ:BBIO

Ionis Pharmaceuticals NASDAQ:IONS

Pfizer NYSE:PFE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools